Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Dec 18, 2022 10:15pm
199 Views
Post# 35178894

RE:Few understand and appreciate

RE:Few understand and appreciateAnd the other alias that appears.What is your motivation?
Again, identify one statment that I said that is untrue:
Actually, everything I post is substantiated by the company "investor presentation"
please don't take my word, check it out.
there are those who post under multiple names, personally attacking those who happen to take the time to read what is going on.
a quick read, confirms 
recent fast track designation for the Roche/ Onc pancreatic drug combination.
recent update from China partner A.N. Confirming postitive results which will be part of upcoming phase 3 MBc trial criteria.
i could go on...please take your time. Go to the investor presentation.
after all I could be spewing B.S . As suggested.
Or perhaps the suggestor is just throwing mud to see what sticks.
My motive , I have explained & wide open.
I own a lot of Onc shares & hope to do very well when they do commercialize Pelareorep.
Same goal founding senior managers have had since day one!
Getting Pela to market.
Will it happen?
ask Roche, Pfizer, Incyte & Merck , who all are in collaborations with oncolytics biotech.
They too are looking for an end game market for Pela alongside thier existing cancer drugs.

now with not just one ( MBc with Pfizer) but also a second opportunity ( panc cancer with Roche).
I challenge the accuser , to identify one single word of what I have posted as False.
be exact....this is not kindergarten.
<< Previous
Bullboard Posts
Next >>